JP2020529864A5 - - Google Patents
Info
- Publication number
- JP2020529864A5 JP2020529864A5 JP2020520427A JP2020520427A JP2020529864A5 JP 2020529864 A5 JP2020529864 A5 JP 2020529864A5 JP 2020520427 A JP2020520427 A JP 2020520427A JP 2020520427 A JP2020520427 A JP 2020520427A JP 2020529864 A5 JP2020529864 A5 JP 2020529864A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- triplicate
- binding specificity
- acid sequence
- percentage homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524554P | 2017-06-25 | 2017-06-25 | |
| US62/524,554 | 2017-06-25 | ||
| PCT/US2018/039153 WO2019005637A2 (en) | 2017-06-25 | 2018-06-22 | MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529864A JP2020529864A (ja) | 2020-10-15 |
| JP2020529864A5 true JP2020529864A5 (enExample) | 2022-02-07 |
| JP7356970B2 JP7356970B2 (ja) | 2023-10-05 |
Family
ID=64742648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520427A Active JP7356970B2 (ja) | 2017-06-25 | 2018-06-22 | 多重特異性抗体とその作製及び使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11649286B2 (enExample) |
| EP (1) | EP3645050A4 (enExample) |
| JP (1) | JP7356970B2 (enExample) |
| CN (1) | CN111148761B (enExample) |
| WO (1) | WO2019005637A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| TWI828625B (zh) * | 2017-06-25 | 2024-01-11 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質以及彼之製造及使用方法 |
| JP7164596B2 (ja) * | 2017-08-28 | 2022-11-01 | システィミューン， インク． | 抗ｃｄ３抗体とその作製及び使用方法 |
| CA3089230A1 (en) * | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
| IL294368A (en) * | 2020-01-29 | 2022-08-01 | Merus Nv | Means and method for modulating mixed effects in immune cells |
| TWI888487B (zh) * | 2020-02-14 | 2025-07-01 | 日商協和麒麟股份有限公司 | 與ｃｄ３結合之雙特異性抗體 |
| PL4269444T3 (pl) | 2020-08-14 | 2025-01-13 | GammaDelta Therapeutics Limited | Wieloswoiste przeciwciała anty-tcr zmienne delta 1 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| WO2022094299A2 (en) * | 2020-10-30 | 2022-05-05 | Janux Therapeutics, Inc. | Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof |
| US20250074996A1 (en) * | 2021-02-19 | 2025-03-06 | Innovent Biologics (Suzhou) Co., Ltd. | ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF |
| CN114853897B (zh) * | 2021-04-15 | 2024-01-26 | 北京大学深圳研究生院 | 抗cd19/cd22/cd3三特异性抗体及用途 |
| AU2022260298A1 (en) * | 2021-04-23 | 2023-11-02 | Shanghai Henlius Biotech, Inc. | Anti-gpc3 antibodies, multispecific antibodies and methods of use |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| CN115305237B (zh) * | 2022-07-08 | 2023-07-14 | 中南大学 | 一种优化的调节性t细胞的扩增及规模化生产的方法 |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
| TW202436358A (zh) * | 2023-03-01 | 2024-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｆａｐ／４－１ｂｂ／ｃｄ４０結合分子及其醫藥用途 |
| CN121398845A (zh) * | 2023-07-14 | 2026-01-23 | 嘉和生物药业有限公司 | 抗pd-1/ctla-4/tigit三特异性抗体及其用途 |
| WO2025059589A1 (en) * | 2023-09-13 | 2025-03-20 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Immune cell engaging molecules |
| WO2026052000A1 (zh) * | 2024-09-04 | 2026-03-12 | 上海迈晋生物医药科技有限公司 | 包含fap/4-1bb/cd40结合分子的药物组合物及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| WO2010028796A1 (en) * | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Trispecific hexavalent antibodies |
| EP2646468B1 (en) * | 2010-12-01 | 2018-07-25 | AlderBio Holdings LLC | Anti-ngf compositions and use thereof |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| SG11201509361TA (en) * | 2013-05-28 | 2015-12-30 | Numab Ag | Novel antibodies |
| CN105722859B (zh) * | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| CA2955947A1 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| EP3204415B1 (en) * | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| US10526404B2 (en) * | 2015-04-29 | 2020-01-07 | Institute For Research In Biomedicine | Multispecific anti GM-CSF antibodies |
| HRP20211058T8 (hr) * | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| CA2998174A1 (en) * | 2015-09-15 | 2017-03-23 | Amgen Inc. | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof |
-
2018
- 2018-06-22 EP EP18825382.7A patent/EP3645050A4/en active Pending
- 2018-06-22 US US16/615,117 patent/US11649286B2/en active Active
- 2018-06-22 JP JP2020520427A patent/JP7356970B2/ja active Active
- 2018-06-22 WO PCT/US2018/039153 patent/WO2019005637A2/en not_active Ceased
- 2018-06-22 CN CN201880039398.6A patent/CN111148761B/zh active Active
-
2023
- 2023-04-06 US US18/296,871 patent/US20230322920A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529864A5 (enExample) | ||
| JP2020530777A5 (enExample) | ||
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2021519072A5 (enExample) | ||
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2021119149A (ja) | 二重特異性四価抗体並びにその製作及び使用方法 | |
| CA3108915A1 (en) | Proteins binding nkg2d, cd16 and a tumor-associated antigen | |
| JP2020501531A5 (enExample) | ||
| JP2020531043A5 (enExample) | ||
| CN117285641A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| Urbanska et al. | Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells | |
| JP2021501575A (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| Sapski et al. | Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response | |
| Fine et al. | Mechanism-driven design of multispecific antibodies for targeted disease treatment | |
| HK40111323A (zh) | 多特异性抗体及其制备和使用方法 | |
| HK40111322A (zh) | 多特异性抗体及其制备和使用方法 | |
| HK40093821A (zh) | 多特异性抗体及其制备和使用方法 | |
| HK40088417A (zh) | 多特异性抗体及其制备和使用方法 | |
| HK40097105A (zh) | 双特异性抗体及其制备和使用方法 | |
| Li et al. | Advancing immunotherapy via multiple immune cells co-engagement | |
| HK40109798A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| HK40097671A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| HK40097672A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| NZ760913B2 (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40018991A (en) | Multi-specific antibodies and methods of making and using thereof |